Dr Christina Reith
|Tel||+44 (0)1865 743743|
- Individual participant data meta-analyses of adverse event data from randomized controlled trials of statin therapy Research Group
- Individual patient meta-analyses of randomized trials of antithrombotic treatments in cardiovascular disease Research Group
- ATT: Antithrombotic Trialists' Collaboration Research Group
- CTT: Cholesterol Treatment Trialists' Collaboration Research Group
- Trials Methodology Research Group
- Research Regulation Research Group
BSc (Hons), MBChB (Hons), FRCP, FFPM
Senior Clinical Research Fellow
Christina studied at The University of Glasgow, gaining a first class honours degree in medical biochemistry and subsequently her medical degree (with honours), when she was jointly awarded the Brunton Medal for the most distinguished graduate in medicine.
Christina completed her MRCP whilst working in the NHS. She joined CTSU in 2004 to work on large-scale clinical trials in relation to cardiovascular disease. She has worked closely on the Study of Heart and Renal Protection (SHARP), the largest ever trial in patients with moderate-to-severe chronic kidney disease (CKD), recruiting 9438 patients in nearly 400 hospitals in 18 countries. She also works on meta-analyses such as those conducted by the Cholesterol Treatment Trialists’ (CTT) and Antithrombotic Treatment Trialists’ (ATT) Collaborations, and is a member of the international Clinical Trials Transformation Initiative (CTTI) and Sensible Guidelines groups which consider how best to conduct trials efficiently.
Christina completed her Royal College of Physicians specialist training in Pharmaceutical Medicine in 2011, became a Fellow of The Royal College of Physicians and Surgeons of Glasgow in 2012 and a Fellow of the Faculty of Pharmaceutical Medicine in 2013. Her research interests include drug safety, in particular the reliable assessment of drug side effects using large-scale randomized data.
Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP).
Staplin N. et al, (2016), Am J Kidney Dis, 68, 371 - 380
Streamlining Safety Data Collection in Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Trials: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team.
Donnelly H. et al, (2016), Clin Infect Dis, 63 Suppl 2, S39 - S45
Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials
Herrington W. et al, (2016), The Lancet Diabetes and Endocrinology
Protocol for analyses of adverse event data from randomized controlled trials of statin therapy
(2016), American Heart Journal, 176, 63 - 69
Management of residual risk after statin therapy.
Reith C. and Armitage J., (2016), Atherosclerosis, 245, 161 - 170